DUBLIN, IRELAND, January 25th 2022 –The National Institute for Bioprocessing Research and Training (NIBRT) today published its Annual Report for 2021 which highlights a 14% growth in revenue and the strongest financial performance of the institute to date.
Despite the challenges imposed by the second year of the Covid-19 pandemic, the outlook for the global biopharma industry is for continued strong growth. Global sales of biopharmaceuticals are now over $300 billion, with a compound annual growth rate of 12% and with approximately 60% of therapeutics in development being biopharmaceuticals. In parallel, the Irish biopharma industry continued to lead the response to the many challenges of the pandemic demonstrating its resilience in global supply chains. New foreign direct investment from Pfizer, Takeda, Amgen and others and the growth of the indigenous sector were welcomed throughout the year. NIBRT continued its strong support of the sector with some of the key achievements in the year including:
- A 14% growth in revenue and the strongest financial performance of the institute to date
- Delivering 39,000 days of learning to over 4,600 trainees
- Welcoming new global partners with Korean-NIBRT (K-NIBRT) and the Canada Alliance for Skills and Training in Lifesciences (CASTL)
- The continued expansion and success of NIBRT research teams, including the award of the €7.23M Disruptive Technology Innovation Fund in partnership with Avectas and Bluebridge Technologies
- The impressive growth of the NIBRT Online Academy with 10,000 users in over 66 countries
- Development of a strong pipeline for 2022, despite significant uncertainties and risks persisting due to the Covid pandemic
Announcing the Annual Report NIBRT CEO, Darrin Morrissey stated “Against the continued Covid-19 backdrop, NIBRT – as one of Ireland’s strategic research and training institutes – had a highly successful year in 2021 in delivering our world-leading services to clients nationally and internationally. I am delighted to report that 2021 saw the organisation out-perform the targets set in our current five-year business plan and achieve record revenues.”
NIBRT Chairman, Brendan O’Callaghan Executive Vice President, Global Industrial Affairs, Sanofi noted “Since opening its facility in 2011 NIBRT has developed a global reputation built on solid foundations. We look forward to continuing to partner with all our stakeholders, to help us further enhance this hard-earned reputation.”
As the Institute looks forward to contributing to the economic recovery post Covid-19, O’Callaghan commented “as we look ahead to 2022, the Board will be focusing on NIBRT’s performance in supporting the continued development of the biopharma sector and developing the next 5-year business plan cycle for the Institute. We look forward to constructing the new Cell and Gene Therapy facility, subject to the necessary approvals, which will further advance Ireland’s capabilities to provide cutting edge research and learning in these rapidly emerging therapies”.
The NIBRT 2021 Annual Report can be downloaded here.
The National Institute for Bioprocessing Research and Training (NIBRT) is a global centre of excellence for training and research in biopharmaceutical manufacturing. NIBRT is located in a world class facility in Dublin, Ireland. This facility is purpose built to closely replicate a modern bioprocessing plant with state-of-the-art equipment and enables NIBRT to offer the highest quality training and research solutions. NIBRT’s mission is to support the growth and development of all aspects of the biopharmaceutical manufacturing industry.
For more information go to www.nibrt.ie
Killian O’Driscoll, NIBRT Director of Projects, +353 1 215 8100, email@example.com